Newsroom - Ipsen US

As the COVID-19 pandemic reaches a critical stage in several countries around the world, we at Ipsen remain firm in our commitments to our employees, our communities and patients. Our…

US

June 30, 2020

Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde®) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer

US

March 11, 2020

Multi-National PRESTO Study Presented by ENETS with Simultaneous Publication in Advances in Therapy

US

SMD-US-003889_SomatulineDepot_PressRelease.pdf

September 26, 2019

Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy

US

Dysport-PULS-Approval-Press-Release_9.26.19_FINAL.pdf

September 8, 2019

Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer

US

Ipsen_Onivyde_1st_Line-World_GI_Data_Presentation_Press_Release.pdf

July 5, 2019

Ipsen and Servier announce initial Phase 1/2 clinical data evaluating liposomal irinotecan (ONIVYDE®) as an investigational first-line treatment for metastatic pancreatic cancer at ESMO 21st World Congress on Gastrointestinal Cancer

US

Ipsen_Onivyde_1st_Line-World_GI_Data_Presentation_Press_Release.pdf

June 24, 2019

Ipsen Announces U.S. FDA Approval for Newly Designed Pre-Filled Syringe for Somatuline® Depot (lanreotide)

US

Ipsen_SD_NDS_Approval_Press_Release_6.24.19.pdf

June 20, 2019

Ipsen Celebrates Opening of New Cambridge Headquarters with Day of Service

US

Grand_Opening_Day_of_Service_Release_6.19.19.pdf

October 21, 2018

Ipsen Presents Real-World Pancreatic Cancer Data on ONIVYDE® at the European Society for Medical Oncology (ESMO) 2018 Annual Congress

US

NON-US-00681_Ipsen-ESMO-Data-Release_10.20.18-FINAL.pdf

October 5, 2018

Ipsen Presents Data on Somatuline® Depot at the North American Neuroendocrine Tumor Society (NANETS) Annual Symposium

US

October 3, 2018

Ipsen Joins Biotechnology Innovation Organization (BIO) To Advance Growth and Innovation

US

June 7, 2018

Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts

US

April 23, 2018

Ipsen Announces Efficacy and Safety Data for Dysport® (abobotulinumtoxinA) Across Multiple Therapeutic Uses at the 2018 Annual Meeting of the American Academy of Neurology

US

February 15, 2018

Ipsen Announces Dysport® (abobotulinumtoxinA) Data Presentations Highlighting Duration of Response and Potential Benefit of Repeated Treatment in Spasticity

US

January 17, 2018

Ipsen to Present Data at ASCO GI 2018, Including New Post-Hoc Analyses from ONIVYDE® (irinotecan liposome injection) Phase 3 NAPOLI-1 Trial

US

January 12, 2018

Ipsen appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America

US

October 12, 2017

Ipsen Announces Five Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly

US

October 11, 2017

Ipsen Joins PhRMA to Continue Advancing Research and Innovation

US

October 4, 2017

Ipsen Announces Four Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Child Neurology Society Annual Meeting Data Includes Analyses of Treatment Utilization and Managed Medicaid Costs for Pediatric Patients with Cerebral Palsy

US

September 18, 2017

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome

US

September 14, 2017

Ipsen Announces Oral and Poster Presentations of abobotulinumtoxinA Data at the 2017 Annual Meeting of the American Academy of Cerebral Palsy and Developmental Medicine Presentations Include Data on Time to Retreatment for Pediatric Patients with Lower Limb Spasticity

US

June 30, 2017

Ipsen announces Dysport® (abobotulinumtoxinA) co-promotion agreement with Saol Therapeutics to expand commercial reach in the United States

US

April 19, 2017

Ipsen Biopharmaceuticals, Inc. Announces Five Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Annual Meeting of the American Academy of Neurology

US

March 21, 2017

Blazing New Trails™: Updates in the Care of Children with Cerebral Palsy

US

February 9, 2017

Ipsen Biopharmaceuticals, Inc. Announces Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Annual Meeting of the Association of Academic Physiatrists

US

January 18, 2017

Ipsen Biopharmaceuticals, Inc. Announces Poster Presentations at ASCO 2017 Gastrointestinal Cancers Symposium

US

January 9, 2017

Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals

US

October 26, 2016

Ipsen Biopharmaceuticals, Inc. Announces Data Presentations at the 2016 Annual Meeting of the Child Neurology Society

US

October 19, 2016

Ipsen Biopharmaceuticals, Inc. Announces Data Presentations at the Annual Meeting of the American Academy of Physical Medicine & Rehabilitation

US

September 30, 2016

Ipsen Biopharmaceuticals, Inc. Announces Nine Poster Presentation at the 2016 North American Neuroendocrine Tumor Society (NANETS Symposium Ipsen Shows Commitment to Continued Research

US

September 21, 2016

Ipsen Announces Data Presentation for Dysport® (abobotulinumtoxinA) at American Academy of Cerebral Palsy and Developmental Medicine

US

August 1, 2016

Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients aged two and old

US

June 4, 2016

Endocrine Practice Publishes ELECT Phase III Trial Results in Adults with Carcinoid Syndrome

US

June 2, 2016

Ipsen Announces Data Presentations of Somatuline® Depot (lanreotide) Injection in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting

US

April 6, 2016

Carcinoid Cancer Foundation and Self Care Catalysts Inc. to Provide a Free Digital Patient Support Application for Carcinoid and Neuroendocrine Tumor (NET) Patients, Sponsored in Part by Ipsen Biopharmaceuticals, Inc.

US

October 22, 2015

Presentation of Results at the AACPDM Annual Meeting from a Phase III Trial Evaluating an Investigational Use of AbobotulinumtoxinA (Dysport®) in Children with Spastic Equinus Foot Deformity due to Cerebral Palsy

US

October 15, 2015

Ipsen Announces Eight Studies of Somatuline® Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors Being Presented at the North American Neuroendocrine Tumor Society (NANETS) Symposium

US

August 31, 2015

Ipsen announces The Lancet Neurology publishes Dysport® Phase III registration trial results in adult patients with upper limb spasticity (ULS)

US

August 4, 2015

IPSEN BIOPHARMACEUTICALS, INC. RECEIVES STATEWIDE AWARD FOR ACHIEVEMENTS IN PRODUCT STEWARDSHIP

US

May 14, 2015

Ipsen Announces Data Presentations for Somatuline® Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting

US

January 13, 2015

Ipsen Biopharmaceuticals To Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline® Depot® (lanreotide), at Gastrointestinal Cancers Symposium

US

December 16, 2014

Ipsen announces the FDA Approval of Somatuline®Depot®(lanreotide) Injection for the treatment of gastroenteropancreatic neuroendocrine tumors

US

December 1, 2014

Ipsen Biopharmaceuticals, Inc. Announces FDA Acceptance of Filing for Dysport® (abobotulinumtoxinA) in the Treatment of Upper Limb Spasticity in Adult Patients

US

November 24, 2014

Ipsen Biopharmaceuticals, Inc. Announces IPSEN CARES™, An Enhanced Patient Support Program

US

November 14, 2014

Ipsen Biopharmaceuticals, Inc. Presents Dysport® (abobotulinumtoxinA) Data at American Academy of Physical Medicine and Rehabilitation Annual Assembly

US

November 5, 2014

Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology

25 years of experience in pharmaceuticals and biologics, including neurotoxins BASKING RIDGE, N.J. November 5, 2014 – Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced…

US

September 18, 2014

COMPANY RESEARCH NOTE

US

September 10, 2014

Ipsen Biopharmaceuticals, Inc. Announces Key Medical and Commercial Hires

US

Choose your location:

Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva

Onivyde® regimen demonstrated statistically significant improvement in overall survival in previously untreated metastatic pancreatic ductal adenocarcinoma

Ipsen to Highlight Expanded Oncology Portfolio and Advances in Follicular Lymphoma Research at ASH 2022

Ipsen statement on updated timeline for palovarotene FDA Advisory Committee meeting

Ipsen completes acquisition of Epizyme expanding its portfolio in oncology

Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission

Ipsen to acquire Epizyme, expanding its portfolio in oncology

IPSEN SPONSORS PANCREATIC CANCER ACTION NETWORK’S PURPLESTRIDE WALK

Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

Ipsen appoints Stewart Campbell Executive Vice President and President of North America

Ipsen adds another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3

Ipsen announces withdrawal of palovarotene NDA, confirming intention to re-submit following additional data analyses

Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders

Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway

Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease

Ipsen confirms U.S. FDA accepts New Drug Application for palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP)

Ipsen receives FDA Fast Track designation for investigational irinotecan liposome injection (ONIVYDE®) as a second-line monotherapy treatment for small cell lung cancer (SCLC)

Ipsen to present new insights at ASBMR for potential treatment of ultra-rare disease fibrodysplasia ossificans progressiva (FOP), including global Phase III MOVE trial results

Ipsen to present results from MOVE, the first global Phase III trial in fibrodysplasia ossificans progressiva (FOP), at ASBMR 2020 annual meeting

Ipsen Announces Updated Indication for Dysport® (abobotulinumtoxinA) for the Treatment of Spasticity in Children

Fulfilling our commitment to employees and mission to patients in the context of the COVID-19 pandemic